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Abstract
Background: Increased urinary albumin excretion rate is the earliest clinical manifestation of diabetic nephropathy.
The development of microalbuminuria in patients with type 1 diabetes mellitus (T1D) usually begins 5 to 15 years
after the onset of diabetes. The rate of progression of diabetic nephropathy varies considerably among patients and
not always can be explained solely by glycaemic control. The evidence suggests that genetic susceptibility may
play a role in the development of diabetes microvascular complications, besides the presence of such risk factors as
hyperglycaemia, hypertension, dyslipidaemia and smoking. The aim of the study was to evaluate a link between
known genetic risk factors for type 1 diabetes mellitus (HLA-DR3/DR4) and microalbuminuria among patients with
the same durations of diabetes.
Methods: Ninety-nine patients with T1D at the age 18–35 years were recruited for the study. The urine albumin
excretion rate was normal when <30 mg/24 h; microalbuminuria 30–300 mg/24 h. Genotypes were investigated in
39 patients with normal albumin excretion rate and duration of diabetes 13.46 ± 3.72 years and in 60 patients with
microalbuminuria and duration of diabetes 15.28 ± 4.08 years (p = 0.11). Genetic typing of DR3 and DR4 antigens
successfully was performed for 99 subjects. Statistical analysis was performed using SPSS v. 20.0.
Results: Genotyping of 99 patients with T1D was performed: no DR3 and DR4 risk alleles were found in 22
(22.22 %) cases, DR3 alleles were present in 47 (47.48 %) cases, DR4 alleles in 25 (25.25 %) cases, and DR3/DR4
alleles in 5 (5.05 %) cases. The highest 24 h albumin excretion rate was found in patients with DRB1 gene expressed
DR3 risk alleles group, the lowest - in patients with DRB1 gene with no expression of both DR3 and DR4 antigen. We
confirmed the 1.87 (p = 0.021) increased relative risk for microalbuminuria in patients with DR3/DR3 alleles and same
duration of diabetes. The distribution of DR3 and DR4 risk alleles was not associated with cardiovascular autonomic
neuropathy both in patients with normal albumin excretion rate and microalbuminuria (1.6 vs 2.1; p = 0.21).
Conclusions: The 1.87 (p = 0.021) increased relative risk for microalbuminuria was found in patients with DR3/DR3
alleles and the same duration of diabetes.
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Background
Type 1 diabetes is a complex disease, the course of
which is influenced by many interacting genetic and en-
vironmental factors [1]. Glycaemic control and diabetes
duration are the most important risk factors for the de-
velopment of late diabetic complications. However, the
rate of progression of nephropathy, retinopathy and
neuropathy varies considerably among patients and not
always can be explained solely by glycaemic control.
Diabetic nephropathy is one of the most threatening
complications of T1D, and its rate and severity directly
correlates with the duration of T1D [2]. The presence of
diabetic nephropathy is related with the greatest risk of
premature death in patients with T1D [3]. Patients with
diabetic nephropathy are likely to have neurological
complications of diabetes including cardiovascular auto-
nomic neuropathy (CAN), the most often overlooked
serious complication of diabetes [4]. Therefore, it is very
important to detect kidney damage early and to stabilize
effectively, because it is reversible in the initial stages
[5]. Microalbuminuria is an early sign of diabetic ne-
phropathy. The development of microalbuminuria in pa-
tients with T1D usually begins 5 to 15 years after the
onset of diabetes and then increases over time, a small
proportion of patients develop microalbuminuria within
less than 5 years of disease onset [6, 7]. Clinical
nephropathy usually occurs after 15–25 years diabetes
duration and rarely newly develops when T1D duration
is more than 30 years [8].
The mechanisms of development of diabetic nephropa-
thy are not fully clear. The evidence suggests that genetic
susceptibility may play a major role in the development of
microvascular complications, besides the presence of such
risk factors as hyperglycaemia, hypertension, dyslipidaemia
and smoking. Based on underlying pathogenesis, polymor-
phisms of several candidate genes belonging to multiple
pathways have been investigated, like the genes related to
mechanisms of hyperglycaemia-induced damage (such as
advanced glycation end-products and reactive oxygen spe-
cies increased formation, augmented activity of the aldose
reductase pathway); genes related to the renin-angiotensin
system; genes coding for cytokines, growth factors and its
receptors, glucose transporters; among many others [9].
The Major Histocompatibility Complex (MHC) region
on chromosome 6p21 has been robustly replicated as a
major risk locus in many immune-mediated diseases, in-
cluding T1D. Certain haplotypes of human leukocyte anti-
gen (HLA) genes are known to confer the main genetic risk
or protection within the MHC region [1]. The major T1D
susceptibility locus maps to the class II loci HLA-DRB1
and HLA-DQB1 on chromosome 6p21. The highest risk
DR/DQ haplotypes for T1D are DR3-DQA1*0501-
DQB1*0201 (DR3) and DR4-DQA1*0301-DQB1*0302
(DR4). Both DR3and DR4 are very strongly associated with
T1D: over 93 % of T1D patients have at least one of these
alleles, compared to 43 % of controls [10]. Other non-HLA
T1D loci in combination have smaller effects on disease
risk compared to HLA [11].
The aim of the study was to evaluate a link between
known genetic risk factors for type 1 diabetes mellitus
(HLA-DR3/DR4) and microalbuminuria.
Methods
Ninety-nine patients with T1D at the age 18–35 years
were recruited for the case–control study. The following
standard-case definition criteria for T1D were used: diag-
nosed as diabetic patient by physician; placed on insulin
therapy before the 30th birthday; resident of his/her coun-
try at the time of the first insulin administration [12]. The
anamnesis of microalbuminuria, hypertension renal failure
or consumption of such drugs like ACE (angiotensin-con-
verting-enzyme) inhibitors or ARB (aldosterone receptor
blockers) was the exclusion criteria in our study. The in-
formation about patients was received from endocrinolo-
gists and general practitioners of Kaunas County.
The evaluation 24 h urine albumin excretion rate (AER)
was based on C. Mogensen [13]: normal AER <30 mg/
24 h; microalbuminuria - AER 30–300 mg/24 h, macroal-
buminuria - AER >300 mg/24 h. Subjects with macroalbu-
minuria, - AER >300 mg/24 h were excluded from
investigation. Genotypes were investigated in 39 patients
with normal AER and duration of T1D 13.46 ± 3.72 years
(cases) and in 60 patients with microalbuminuria and dur-
ation of diabetes 15.28 ± 4.08 years (controls) (p = 0.11).
Genetic typing of DR3 and DR4 antigens was performed
for all 99 subjects. The diagnosis of CAN was based on
the results of a battery of autonomic tests (heart rate at
rest, heart rate response to deep breathing, standing up,
systolic blood pressure response to standing up and dia-
stolic blood pressure response to isometric exercise). The
diagnosis of CAN was confirmed when 2 or more patho-
logical tests were present. Standardised questionnaires
were completed to obtain information on demographic
data, clinical events, medications and life style.
The study protocol was approved by the local Ethics
committee of Lithuanian University of Health Sciences
(Kaunas city); all participants provided written informed
consent.
Methods of genotyping
DNA was extracted from peripheral blood leukocytes by
salt precipitation. The isolated DNA was dissolved in
sterile 1xTE buffer. Isolated DNA concentration was
measured with a spectrophotometer, and purity was
assessed by measuring the optical density.
Investigated DNA fragment was amplified with PCR
reaction using 100 ng of subjects DNA, dNTP mix, Taq
polymerase, 1.25 Dream U and reaction buffer. Specific
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primers were used for amplification of 213 bp (base
pairs) PCR fragment size, which create an artificial re-
striction fragment length polymorphism in DRB1 gene -
DR3 RFLP: 5′ CCG CTG CAC TGT GAA GCT CTC
CAC AAC CCC GTA GTT GTG TCT GCA CTAG 3′
and DR4.04: 5′ CGG GTG CGG TTC CTG GAC AGA
TAC TTC GAT 3′. PCR was performed using gradient
Eppendorf firm thermal cycler. PCR reaction products
were visualised on 1.5 % agarose gel. Restriction reaction
was performed using 5 units of restriction endonuclease
Spe 1 (Enzyme) and 1 Dde (Enzyme) in 15 μl of reaction
mixture (composition - 5 μl of the PCR product, restric-
tion endonuclease Spe 1 and 0.5 μl Dde, 1.5 ul 10× reac-
tion buffer and 7.5 μl of water). After 2 h Sau 3A1
enzyme, which recognizes GATC sequence in DR4 allele
was added and a fragment of 186 bp is obtained.
Restriction of ACTAGT sequence, which presents only
in DR3 or DRB7 allele, was recognized by restriction of
endonuclease Spe 1 and obtained fragment of 164 bp. Dde
1 allows to distinguish between DR3 or DRB7 alleles be-
cause it recognizes two places of CTNAG in DRB7 allele
(codons 51–52 and 58–59), and neither one place in DR3
allele. If it is DRB7 allele Dde 1 cuts PCR into three frag-
ments of 106, 86, and 21 base pairs. If Dde cutting site is
located on another allele, there is no the second cutting
site, and are presented 106/107 bases duplets.
Restriction fragment size was evaluated in 4 % agarose
gel after electrophoresis and colouring EtBr. Gel was
documented and restriction fragment sizes were assessed
using BioRad gel documentation system.
The assessment of HLA genotyping results:
N/N – DRB1 gene does not express neither DR3 nor
DR4 antigen (both alleles determine the absence of
DR3 and DR4 antigen - homozygote);
DR3/DR3 – subject has DR3 antigen (both alleles
determine DR3 antigen- homozygote);
DR4/DR4 – subject has DR4 antigen (both alleles
determine DR4 antigen- homozygous);
DR3/DR4 – subject has DR3 and DR4 antigens
(heterozygote);
DR3/N – subject has DR3 antigen (heterozygote);
DR4/N – subject has DR4 antigen (heterozygote).
Statistical analysis
Statistical analysis was performed using SPSS v. 20.0
(License No. 9582494). The sample size was calculated
during a pilot study using PASS (Power analysis and
sample size software). The power of the study was se-
lected to be β = 0.8, and the confidence level - α = 0.05.
Data are presented in absolute value and frequency.
Data are presented as means and standard deviations.
Used statistical methods: variables of two independent
samples were compared using a Mann–Whitney test.
Chi-square (χ2) was used for rates comparison. Risk al-
leles search was performed using univariate odds ratio
analysis. Results were interpreted as statistically sig-
nificant at an error probability of p <0.05.
Results
The 99 patients with T1D (47 males and 52 females)
were included in the study. Genotypes in two homoge-
neous groups according to the age of T1D diagnosis,
duration of diabetes, gender and HbA1c were analysed.
The characteristics of patients are summarized by AER
status in Table 1. The proportion of CAN was signifi-
cantly greater in case group (6.81 %) as compared with
control group (2.32 %) (p = 0.03).
The highest 24 h AER was found in patients with DRB1
gene expressed DR3 risk alleles group. The lowest AER
was found in patients with DRB1 gene with no expression
of both DR3 and DR4 antigen (Table 2). Assessing DRB1
gene’s N/N, DR3 and DR4 risk alleles combinations and
microalbuminuria, the greatest significance was achieved
between N/N and DR3 alleles groups.
Genotyping of 99 patients with T1D was performed:
no DR3 and DR4 risk alleles were found in 22 (22.22 %)
patients, DR3 alleles were present in 47 (47.48 %), DR4
Table 1 Characteristics of the study subjects according to AER
Normal AER (control patients) 30 < AER <300 mg/24 h (case patients) 2- tailed p
n 39 60
Age at diagnosis (years) 12.25 ± 6.12 13.61 ± 5.41 0.26
Age at entry (years) 26.53 ± 7.89 29.37 ± 5.56 0.19
Duration of diabetes (years) 13.46 ± 3.72 15.28 ± 4.08 0.11
Gender (M/F) 18/21 29/31 0.31
HbA1c (%) 7.8 8.0 0.43
Systolic blood pressure (mmHg) 123 ± 11 125 ± 13 0.38
Diastolic blood pressure (mmHg) 75 ± 8 78 ± 10 0.40
CAN (%) 2.32 6.81 0.03
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alleles in 25 (25.25 %), and DR3/DR4 alleles in 5
(5.05 %) (Table 3). According to the frequency of differ-
ent combinations of alleles we didn’t find statistical dif-
ference among case (AER 30–300 mg/24 h) and control
(AER <30 mg/24 h) groups.
We compared by DRB1 gene’s N/N, DR3 and DR4 risk
alleles in patients with T1D, most case patients had DR3
risk alleles: 31 (51.67 %) patient had DR3 alleles, 13
(21.67 %) patients had DR4 alleles and 4 (6.67 %) patients
had DR3/DR4 alleles. We confirmed the 1.87 (p = 0.021)
increased relative risk for microalbuminuria in patients
with DR3/DR3 alleles and the same duration of diabetes
(Table 4).
The distribution of DR3 and DR4 risk alleles was not
associated with CAN both in patients with normal AER
and microalbuminuria (1.6 vs 2.1; p = 0.21).
Discussion
Microalbuminuria is an early sign of diabetic nephropa-
thy. Microalbuminuria is seldom found in patients
within first 5 years from onset of T1D, usually microal-
buminuria starts at 5 to 15 years of duration of diabetes
and then increases over time [6, 7]. In a systematic re-
view of nine longitudinal studies examining moderately
increased albuminuria in 7938 patients with T1D, the
overall prevalence of moderately increased albuminuria
was 28 % at a mean duration of T1D of 15 years [14].
J.H. Warram and co-authors state that microalbumi-
nuria can be found in about 20 % of patients with type 1
diabetes with duration of disease 20 years and in a 50 %
with duration of disease more than 30 years [7]. For kids
and teens advanced stage of diabetic nephropathy is sel-
dom found [15]. Several studies describe the rapid clin-
ical and histological development of diabetic
nephropathy in children and adolescents at 4–11 years
duration of disease [16, 17]. Familial tendency to develop
this diabetes complication was determined [18], showing
the importance of genetic factors. But still no individual
gene that results in kidney damage in patients with type
1 diabetes was identified.
The impact of apolipoprotein E gene [19], growth
arrest-specific 6 gene (Gas6) and their receptors Ax1 [20],
polymorphism of the enzyme V16A of manganese super-
oxide dismutase [21], insulin gene [22], DQA1 and DQB1
haplotypes [23], HLA-DR3 and DR4 alleles [24] are inves-
tigated to clarify the reasons for the development of dia-
betic nephropathy. HLA has a significant impact not only
to the development of T1D, but also to diabetes complica-
tions. The aim of the study was to evaluate a link between
HLA-DR3/DR4 and microalbuminuria among patients
with the same durations of diabetes.
The highest risk DR/DQ haplotypes for T1D are DR3-
DQA1*0501-DQB1*0201 (DR3) and DR4-DQA1*0301-
DQB1*0302 (DR4), and these alleles account for 30–50 %
of genetic T1D risk [10]. Although 40 % of whites in the
US have an HLA-DR3 or -DR4 allele, at least 1 of these al-
leles is present in 95 % of patients with T1D. The esti-
mated risk of developing T1D for the general population
in children who have the HLA-DR3/4 genotype is ap-
proximately 1 in 15 to 1 in 25 vs. a risk of 1 in 300 in the
general population [25]. Only 2.4 % of the general popu-
lation carries this genotype compared to 30–40 % of
T1D patients. Although this genotype confers extremely
high risk, there is a spectrum of risk associated with
HLA DR/DQ genotypes—from increased, to neutral, to
protective [26].
Table 2 Mean AER (mg) and ±95 % confidence intervals
associated with combinations of alleles





Note: CI confidence intervals
Table 3 Frequency of different combinations of alleles in normal AER and microalbuminuria
N/N DR3/DR3+N/DR3 DR4/DR4+N/DR4 DR3/DR4
n (%) n (%) n (%) n (%)
Normal AER (control patients) 10 (25.64) 16 (41.03) a 12 (30.77) 1 (2.56)
30 < AER <300 mg/24 h (case patients) 12 (20.00) 31 (51.67) a 13 (21.67) 4 (6.67)
2-tailed p 0.44 0.06 0.19 –
Note: aN/N vs DR3/DR3+N/DR3, DR4/DR4+N/DR4, DR3/DR4
Table 4 Univariate analysis of risk of microalbuminuria
according genotypes
Genotype OR ±95 % CI 2-tailed p
N/N 0.62 0.43–0.91 0.392
N/DR3 0.73 0.23–0.87 0.411
N/DR4 0.31 0.24–1.89 0.371
DR3/DR3 1.87 1.21–3.16 0.021
DR4/DR4 0.87 0.67–1.23 0.423
DR3/DR4 – – –
Note: DR3/DR4 - the number of cases in groups 4/1, OR odds ratio, CI
confidence intervals
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Very early small studies looked at HLA in people with
diabetic nephropathy, but no reliable associations was
found [27–29]. The assumption that the HLA DRB1*04
alleles may protect against development of diabetic ne-
phropathy appeared recently. A. Svejgaard et al. investi-
gated 71 patients with long duration of T1D, 24 had
diabetic nephropathy and 51 normal AER, and found a
marked protective effect of DR4 allele (p = 0.02) [30]. In
our study we have found the highest risk of increased
AER in T1D patients with DRB1 gene expressed DR3
risk allele. Also the lowest AER we found in patients
with neither DR3 nor DR4 antigen expressed. Genetics
of Kidneys in Diabetes (GoKinD) study [31], examined
patients with T1D with nephropathy (n = 829) and with-
out nephropathy (n = 904). Results of this study showed,
that diabetic probands who were homozygous for HLA
DRB1*04 were 50 % less likely to have nephropathy than
probands without any DRB1*04 alleles. In heterozygous
carriers, a protective effect of this allele was not as
clearly evident. This association was seen in probands
with both short (<28 years, p = 0.02) and long (≥28 years,
p = 0.0001) duration of diabetes. Interestingly, DRB1*04
appears to be both a risk allele for T1D and a protective
allele for nephropathy. In our study patients who were
homozygous for HLA DRB1*04 were 50 % less likely to
have microalbuminuria than patients who were homozy-
gous for HLA DRB1*03 allele. The main weakness of
our study is the small sample size. The power of the
study was selected to be β = 0.8, and the confidence level
- α = 0.05. We calculated that we need to find 334 pa-
tients (case and controls). Finally we could include and
analyze only 99 patients, so further research is necessary
to confirm our results. The other limitation is that a
population of our study was only caucasians, and pos-
sibly our findings couldn’t be applied to other races.
Conclusions
The 1.87 (p = 0.021) increased relative risk for microal-
buminuria was found in patients with DR3/DR3 alleles
and the same duration of diabetes.
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